A new option for millions looking to try those popular weight loss drugs without having to use a needle. The FDA approving Eli Liy's new GLP1 pill called FO set to hit the market next week. Feoo's selling point takes convenience one step further.Unlike WGOi, you don't have to take FO on an empty stomach and then wait 30 minutes to eat or drink. While not as effective as the injections, both pills help people lose weight. Studies show patients who took the highest dose of Fondo lost 12% of their body weight ...

Another pill to fight obesity won US approval, pitting Lilly’s Foundayo against Novo’s Wegovy pill in the race to dominate a market worth billions. Patients and consumers may also be winners, as prices fall and selection expands. https://t.co/1upjiYnPww ...

The Trump administration is set to announce tariffs as soon as Thursday on drugmakers that haven’t struck deals guaranteeing low prices in the US, according to sources https://t.co/qMTA8crxhZ ...

RT Babak Taghvaee - The Crisis Watch (@BabakTaghvaee1)BREAKING: The Israeli Air Force continued committing another war crime in Iran this afternoon by targeting multiple pharmaceutical facilities. Among them, Darou Pakhsh—one of the largest pharmaceutical manufacturers in Iran—was heavily bombed.The company plays a major role in producing and distributing medicines across the country, making its targeting particularly significant in terms of impact on civilian healthcare infrastructure.#OperationEpicFury #O ...

Earlier this year, Novo Nordisk pulled off the best obesity-drug launch ever with its Wegovy pill and is now building on 600,000+ prescriptions as Eli Lilly threatens with a rival pill https://t.co/qFJemR7WVe ...

The FDA approved Eli Lilly’s new weight-loss pill, setting up a fight with rival Novo Nordisk over the next front in the booming market https://t.co/1j0gqhoXlH ...

FDA Approves Eli Lilly’s Weight Loss Pill—Second Weight GLP-1 Drug In Pill Formhttps://t.co/p5uBtpdUYU https://t.co/DyOwW2Tpvb ...

Eli Lilly & Co.’s weight-loss pill won US approval, ratcheting up pressure on Novo Nordisk A/S, which launched an obesity pill earlier this year. https://t.co/FDknJHod96 ...

Poland and Romania have been ordered by a Belgian court to pay Pfizer Inc. €1.9 billion ($2.2 billion) for Covid-19 vaccines the two countries refused to take delivery of during the pandemic https://t.co/JQLWxNZFjK ...

Core Viewpoint - Marksans Pharma Ltd has received final approval from the USFDA for its generic version of Benzonatate capsules, which are used to treat persistent cough, bronchitis, pneumonia, and other lung infections [1][2]. Group 1: Regulatory Approval - The approval is for the company's abbreviated new drug application (ANDA) for Benzonatate capsules in strengths of 100 mg and 200 mg [1]. - The product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Tessalon Capsules, 100 mg and 200 mg, from Pfizer Inc [2]. Group 2: Product Information - Benzonatate is a non-narcotic antitussive that numbs stretch receptors in the respiratory tract, thereby reducing the cough reflex and relieving symptoms associated with persistent cough, bronchitis, pneumonia, and other lung infections [2].